After Factory Explosion, A Big Retail Pump On Neptune [View article]
Some of the smartest guys on Wall Street have their money in this stock for a reason. Talk about kicking a company when they're down simply so the hedge funds and shorters network can make more money. WOW! I'm loading up at these levels. Thank you!
3 Biotech Giants With High Dividend Yields [View article]
It makes complete sense that AZN is in the mix to acquire AMRN- particularly since they have shut down their internal research and because AMRN is sitting on an FDA approved drug with billions of dollars in market potential. Other big pharmas spend lots of money developing a best in class type drug like AMRN's Vescepa, so why not swoop in an snag it before someone else does? They need more development pipeline.
$GALE is a joke. As some of you may recall. I wrote an article that warned investors to stay away from this firm. I was also bullied but firmly agree with the findings by PropThink and have since done more research on WHO is promoting the stock and why. Suffice it to say investors should be very averse to an investment here. $GALE continues to be mostly a SCAM run by some of the most nepherious players in biotech. I hope regulators take a hard look at this developing situation and snap their whips against those responsible!
Betting On FDA's Vote For Arena Pharmaceuticals? [View article]
It's all about the data and the trading sentiment in biotechs. Make money, take your profits and grow some more money elsewhere. Very few long term "investments" here.
What Can We Expect From CytRx In 2012? [View article]
Grant,
How much were you paid by CYTR to write this fluff piece? Seriously. Are you just another one of the paid promoters who come at the expense of shareholders?
From what I hear, the folks at CYTR aren't willing to answer some of the tough questions I have for them about that and other issues.
I wonder if answers are something we can look forward to in 2012? Either way, one way or another I think we will piece the puzzle together.
Come clean Grant. What's in it for you here? You claim to have no position in the stock.
Are you simply doing us all a favor by educating us as to the investment opportunity at CYTR?
Why not tell us about the possibilities that CYTR investors may have to face a massive reverse split if the firm's Nasdaq listing comes into jeopardy-- again?
Why CytRx Corporation Is Still A Big Biotech 'If' Play [View article]
Well, I guess that I am a somebody now, aren't I Mr. notdumb? And I assure you I have gained nothing financially from exposing the truth here. There are ALL facts. More to come.
Why CytRx Corporation Is Still A Big Biotech 'If' Play [View article]
You're right, Joe pal.. Kreigsman's salary is something I forgot to mention. Still, there is plenty more to write about CYTR and RXII. Stock promoters, IR firms, SEC investigations, Lawyers. Lots more to come.
Neptune More Attractive After Recent Developments [View article]
rads2005, I guess that remains to be seen given how badly the shorts and bashers beat RXPC up. According to the financings they did, it was never supposed to go under $.60 and yet "the tabloid" published 5 articles in one month designed to make sure the stock price went below the floor that was promised the big investors. That sent the company into penalty territory and all the notes suddenly became due.
It's not hard to see after the most recent 8K filings that the company may have the last laugh yet. They made the funds accept so many shares that they turned them into insiders and now they can't get out without being in violation of rule 144. (www.sec.gov/investor/p...)
If Radient can actually start selling their tests and putting out positive news, then it's going to be hard to argue that NEPT is a better investment. Especially since NEPT is already near a top. If you're a bull, then you buy RXPC at the bottom, if you're a bear, then you short NEPT at this top.
Galena Biopharma Now Offers Considerable Long-Term Potential [View article]
See:
http://bit.ly/YeFmtS
And mine: http://seekingalpha.co...
After Factory Explosion, A Big Retail Pump On Neptune [View article]
3 Biotech Giants With High Dividend Yields [View article]
The Other Side Of Galena Biopharma [View article]
Betting On FDA's Vote For Arena Pharmaceuticals? [View article]
What Can We Expect From CytRx In 2012? [View article]
How much were you paid by CYTR to write this fluff piece? Seriously. Are you just another one of the paid promoters who come at the expense of shareholders?
From what I hear, the folks at CYTR aren't willing to answer some of the tough questions I have for them about that and other issues.
I wonder if answers are something we can look forward to in 2012? Either way, one way or another I think we will piece the puzzle together.
Come clean Grant. What's in it for you here? You claim to have no position in the stock.
Are you simply doing us all a favor by educating us as to the investment opportunity at CYTR?
Why not tell us about the possibilities that CYTR investors may have to face a massive reverse split if the firm's Nasdaq listing comes into jeopardy-- again?
Educate me.
Why CytRx Corporation Is Still A Big Biotech 'If' Play [View article]
Why CytRx Corporation Is Still A Big Biotech 'If' Play [View article]
Why CytRx Corporation Is Still A Big Biotech 'If' Play [View article]
Sorry. This is a very easy target to shoot at with cold, hard facts.
Why CytRx Corporation Is Still A Big Biotech 'If' Play [View article]
http://bit.ly/sq2081
Ampio Pharmaceuticals: Straight Out Of Isolagen's Playbook [View article]
You made MarketWatch! Niiice.
http://bit.ly/rSUEmv
Navigating Cancer Vaccines' High-Risk/High-Reward Field [View article]
As to the under the radar ones, you will have to wait to see my new report.
Neptune More Attractive After Recent Developments [View article]
biomedreports.com/2011...
Amarin Must Be Acquired - And There Are Plenty of Potential Suitors [View article]
Neptune More Attractive After Recent Developments [View article]
It's not hard to see after the most recent 8K filings that the company may have the last laugh yet. They made the funds accept so many shares that they turned them into insiders and now they can't get out without being in violation of rule 144. (www.sec.gov/investor/p...)
If Radient can actually start selling their tests and putting out positive news, then it's going to be hard to argue that NEPT is a better investment. Especially since NEPT is already near a top. If you're a bull, then you buy RXPC at the bottom, if you're a bear, then you short NEPT at this top.